LLY

1,067.68

+0.83%↑

JNJ

205.97

+1.01%↑

ABBV

229.49

-2.82%↓

UNH

318.47

-0.28%↓

AZN

91.56

+0.6%↑

LLY

1,067.68

+0.83%↑

JNJ

205.97

+1.01%↑

ABBV

229.49

-2.82%↓

UNH

318.47

-0.28%↓

AZN

91.56

+0.6%↑

LLY

1,067.68

+0.83%↑

JNJ

205.97

+1.01%↑

ABBV

229.49

-2.82%↓

UNH

318.47

-0.28%↓

AZN

91.56

+0.6%↑

LLY

1,067.68

+0.83%↑

JNJ

205.97

+1.01%↑

ABBV

229.49

-2.82%↓

UNH

318.47

-0.28%↓

AZN

91.56

+0.6%↑

LLY

1,067.68

+0.83%↑

JNJ

205.97

+1.01%↑

ABBV

229.49

-2.82%↓

UNH

318.47

-0.28%↓

AZN

91.56

+0.6%↑

Kodu・Aktsiate loetelu・Gossamer Bio Inc

Gossamer Bio Inc

Suletud

SektorTervishoid

3.17 3.93

Osta Müü

Ülevaade

Aktsiahinna muutus

24h

Praegune

Min

2.98

Max

3.22

Põhinäitajad
By Trading Economics
Sissetulek	-9.9M -48M
Müük	1.8M 13M
Aktsiakasum	-0.21
Kasumimarginaal	-362.728
Töötajad	144
EBITDA	-10M -45M

Soovitused
By TipRanks
Soovitused	Tugev "osta" hinnang
12 kuu keskmine prognoos	+252.94% upside

Turustatistika
By TradingEconomics
Turukapital	145M 692M
Eelmine avamishind	-0.76
Eelmine sulgemishind	3.17

Uudiste sentiment

By Acuity

25%

75%

65 / 374 Pingereas Healthcare

Tehniline skoor

By Trading Central

Kindlus

Weak Bullish Evidence

1.06 / 1.23 Toetus ja vastupanu

Gossamer Bio Inc Graafik

Mineviku tootlus ei ole usaldusväärne näitaja tulevaste tulemuste kohta.

Seotud uudised

24. nov 2025, 21:54 UTC

Omandamised, ülevõtmised, äriostud

Exodus Agrees to Acquire W3C Corp in Deal Valued at $175 Million

24. nov 2025, 18:26 UTC

Suurimad hinnamuutused turgudel

Tegna Shares Fall After Trump Blasts Proposal to Lift Broadcast Ownership Cap

24. nov 2025, 23:49 UTC

Market Talk

Nikkei May Rise After Tech Recovery on Wall Street -- Market Talk

24. nov 2025, 23:08 UTC

Market Talk

More Losses Ahead for Steel & Tube, Says New Bear -- Market Talk

24. nov 2025, 23:08 UTC

Market Talk

Global Equities Roundup: Market Talk

24. nov 2025, 22:56 UTC

Market Talk

Tulu

Alimentation Couche-Tard U.S. Sales Gain Momentum -- Market Talk

24. nov 2025, 22:47 UTC

Market Talk

Kiwi Property Can Keep Growing Its Dividend -- Market Talk

24. nov 2025, 22:36 UTC

Market Talk

Tulu

Kiwi Property's 1H Result Cements Bull's Confidence in Outlook -- Market Talk

24. nov 2025, 22:32 UTC

Tulu

Webco Industries 1Q EPS $6.79 >WEBC

24. nov 2025, 22:07 UTC

Tulu

Couche-Tard 2Q Canada Same-Store Merchandise Revenues Up 5.4% >ATD.T

24. nov 2025, 22:07 UTC

Tulu

Couche-Tard 2Q U.S. Same-Store Merchandise Revenues Up 1.2% >ATD.T

24. nov 2025, 22:06 UTC

Tulu

Couche-Tard 2Q Adj EPS 78c >ATD.T

24. nov 2025, 22:06 UTC

Tulu

Couche-Tard 2Q Rev $17.9B >ATD.T

24. nov 2025, 22:06 UTC

Tulu

Couche-Tard 2Q EPS 79c >ATD.T

24. nov 2025, 22:05 UTC

Tulu

Couche-Tard 2Q Rev $17.9B >ATD.T

24. nov 2025, 22:05 UTC

Tulu

Couche-Tard 2Q Net $740.6M >ATD.T

24. nov 2025, 22:05 UTC

Tulu

Couche-Tard 2Q Adj EPS 78c >ATD.T

24. nov 2025, 22:05 UTC

Tulu

Couche-Tard 2Q EPS 79c >ATD.T

24. nov 2025, 21:50 UTC

Market Talk

Omandamised, ülevõtmised, äriostud

Basic Materials Roundup: Market Talk

24. nov 2025, 21:50 UTC

Market Talk

Health Care Roundup: Market Talk

24. nov 2025, 21:44 UTC

Market Talk

Canada Close to MOU With Alberta About New Possible Pipeline -- Market Talk

24. nov 2025, 21:39 UTC

Omandamised, ülevõtmised, äriostud

Exodus Agrees to Acquire W3C Corp in Deal Valued at $175M

24. nov 2025, 20:42 UTC

Market Talk

Oil Futures Snap Three-Session Losing Streak -- Market Talk

24. nov 2025, 20:41 UTC

Market Talk

U.S. Natural Gas Futures Settle Lower -- Market Talk

24. nov 2025, 19:56 UTC

Omandamised, ülevõtmised, äriostud

Nvidia Says It's Not Enron in Private Memo Refuting Accounting Questions -- Barrons.com

24. nov 2025, 18:26 UTC

Market Talk

Crude Futures Move Higher in Choppy Trade -- Market Talk

24. nov 2025, 17:20 UTC

Market Talk

Omandamised, ülevõtmised, äriostud

Basic Materials Roundup: Market Talk

24. nov 2025, 17:20 UTC

Market Talk

Health Care Roundup: Market Talk

24. nov 2025, 17:09 UTC

Market Talk

Brent Could Drop to the $30s Without Production Cuts, JPM Says -- Market Talk

24. nov 2025, 16:52 UTC

Omandamised, ülevõtmised, äriostud

Strategy Silent on Bitcoin Holdings. Why It's a Big Deal for the Stock and Cryptos. -- Barrons.com

Võrdlus sarnastega

Hinnamuutus

Gossamer Bio Inc Prognoos

Hinnasiht

By TipRanks

252.94% tõus

12 kuu keskmine prognoos

Keskmine 10.8 USD 252.94%

Kõrge 15 USD

Madal 8 USD

Põhineb 8 Wall Streeti analüütiku instrumendi Gossamer Bio Inc 12 kuu hinnasihil - viimase 3 kuu andmed.

Hinnangu Konsensus

By TipRanks

Tugev "osta" hinnang

8 ratings

Osta

Hoia

Müü

Põhineb 8 analüütiku instrumendi Gossamer Bio Inc aktsia reitingul - viimase 3 kuu andmed.

Tehniline skoor

By Trading Central

1.06 / 1.23Toetus ja vastupanu

Bullish events outweigh bearish events.

Recent bearish events outweigh bullish events.

All events are bullish.

Sentiment

By Acuity

65 / 374 Pingereas Tervishoid

Finantsandmed

Müügi- ja halduskulud

Tegevuskulud

Maksueelne kasum

Müük

Müügikulu

Brutokasum müügist

Intressikulud võla pealt

EBITDA

Ärikasum

Ettevõttest Gossamer Bio Inc

Gossamer Bio, Inc., a clinical-stage biopharmaceutical company, focuses on developing and commercializing seralutinib for the treatment of pulmonary arterial hypertension (PAH) in the United States. The company is developing GB002, an inhaled, small molecule, platelet-derived growth factor receptor, or PDGFR, colony-stimulatin factor 1 receptor and c-KIT inhibitor, which is in Phase 3 clinical trial for the treatment of PAH. It has license agreements with Pulmokine, Inc. to develop and commercialize GB002 and related backup compounds. The company was formerly known as FSG, Bio, Inc. and changed its name to Gossamer Bio, Inc. in 2017. Gossamer Bio, Inc. was incorporated in 2015 and is headquartered in San Diego, California.